Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
Madhavi Nallam, Venugopalaiah P*, K. Gnana Prakash, M. Gobinath, P. Naresh
Department of Pharmaceutics, Ratnam Institute of Pharmacy, Pidthapolur, Muthkur, Nellore-524346, Andhra Pradesh, India
A B S T R A C T
In the present investigation, an attempt was made to formulate and characterize the oral sustained release matrix tablets of salbutamol sulphate in order to improve efficacy, reduce the frequency of administration and better patient compliance. Salbutamol sulphate selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vaso constrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Matrix tablets of Salbutamol sulphate were formulated using different concentrations of hydrophilic polymers such as HPMCK4M, HPMC K15, HPMC K100 and prepared by Wet granulation method. The powder blend was evaluated for precompression properties. The tablets were evaluated for thickness, weight variation test, hardness, friability, and drug content and in-vitro drug release profile over a period of 12 hours. Along with physical properties, the dynamics of water uptake and erosion degree of tablets were also studied. The in-vitro drug release study revealed that, all the formulations showed extended release for 12 hours but most successful formulation of the study was found to be optimized with drug to polymer combination (0.5:0.5) 1:1 which includes HPMCK4M and HPMC K100, extended the drug release up to 12 hours. Formulation ‘F10’ follows Higuchi’s kinetics indicating zero-order release which can be achieved when drug diffusion is rapid compared to the constant rate of solvent induced relaxation and swelling in the polymer. Results indicated that the prepared sustained-release tablets of Salbutamol sulphate could perform therapeutically better than conventional tablets with improved efficacy and better patient compliance.
Keywords: Salbutamol sulphate, Extended release, HPMCK4M, HPMC K15, HPMC K100 etc
